Pylera® for the eradication of Helicobacter pylori infection

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 7, 2009, Pages 793-799

  Saleem, Aamir ^a   Qasim, Asghar ^a   O'Connor, Humphrey J ^a   O'Morain, Colm A ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Antibiotic resistance; Bismuth biskalcitrate; Helicobacter pylori; Single triple capsule

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH CITRATE; CLARITHROMYCIN; LANSOPRAZOLE; LITHIUM; METRONIDAZOLE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; PYLERA; TETRACYCLINE; UNCLASSIFIED DRUG; ANTACID AGENT; ANTIINFECTIVE AGENT; ANTIULCER AGENT; BISMUTH;

AGRAPHIA; ALCOHOLIC BEVERAGE; ANTIBIOTIC RESISTANCE; ATAXIA; BEHAVIOR DISORDER; BRAIN DISEASE; CLINICAL TRIAL; COLITIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; DYSARTHRIA; DYSPEPSIA; ERADICATION THERAPY; FOOD DRUG INTERACTION; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GINGIVITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEPATITIS; HUMAN; INSOMNIA; KIDNEY DISEASE; MEMORY DISORDER; MENTAL DISEASE; MUSCLE CRAMP; NAUSEA; NEUROTOXICITY; NONHUMAN; OSTEOARTHROPATHY; PATIENT COMPLIANCE; PHARMACODYNAMICS; REVIEW; STOMACH ULCER; STOMATITIS; TASTE DISORDER; VAGINAL PRURITUS; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; MICROBIOLOGY; MICROCAPSULE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTACIDS; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BISMUTH; CAPSULES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; OMEPRAZOLE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRACYCLINE; TREATMENT OUTCOME;

EID: 70350633954     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.55     Document Type: Review

References (90)

1. Coghlan JG, Gilligan D, Humphries H et al. Campylobacter pylori and recurrence of duodenal ulcers - a 12 month follow up study. Lancet 2, 1109-1111 (1987). (Pubitemid 17154827)
2. Marshall BJ, Goodwin CS. Prospective double blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 2, 1437-1442 (1998).
3. Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 335, 1233-1235 (1990).
4. Mitchell HM, Hu P, Chi Y et al. A low rate of reinfection following effective therapy against Helicobacter pylori in a developing nation (China). Gastroenterology 114, 256-261 (1998). (Pubitemid 28093531)
5. Amendola R, Luna P, Farias M. No recurrence of peptic ulcer bleeding after successful eradication of Helicobacter pylori. AGA 1997. Turk. J. Gastroenterol. 11, 212-215 (2000).
6. Labenz J, Blum AL. Curing Helicobacter pylori infection in duodenal ulcer patients may provoke reflux esophagitis. Gastroenterology 112, 1442-1447 (1997). (Pubitemid 27181366)
7. Hopkins RJ, Giradi LS. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 110, 1244-1252 (1996).
8. Koo J, Ho J, Lam SK et al. Selective coating of gastric ulcer by tripotassium dicitrato bismuthate in the rat. Gastroenterology 82, 864-870 (1982).
9. McColl K, Murray L, El-Omer E et al. Symptomatic benefit from eradicating H. pylori infection in patients with nonulcer dyspepsia. N. Engl. J. Med. 339, 1869-1874 (1998).
10. Blum AL, Talley NJ, O'Morain C et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus clarithromycin and amoxicillin effect one year after treatment (OCAY) Study Group. N. Engl. J. Med. 339, 1875-1881 (1998).
11. Talley NJ, Vakil N, Ballard ED 2nd et al. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N. Engl. J. Med. 341, 1106-1111 (1999). (Pubitemid 29466222)
12. Leheij RJ, Rossum LG, Jansen JB et al. Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment. Pharmacol. Ther. 13(7), 857-864 (1999).
13. Ford AC, Delaney BC, Forman D et al. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am. J. Gastroenterol. 99, 1833-1855 (2004).
14. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled data analysis. Gut 56, 1353-1357 (2007). (Pubitemid 47517826)
15. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advantages in testing. Gut 53, 1374-1384 (2004). (Pubitemid 39120130)
16. Fischbach LA, Van Zanten SV, Dickason J. Meta-analysis: the efficacy, adverse effects and adherence related to first line anti-Helicobacter pylori quadruple therapies. Aliment. Pharmacol. Ther. 20, 1071-1082 (2004). (Pubitemid 39657940)
17. Di Mario F, Cavallaro LG, Scarpignato C et al. Rescue therapies for Helicobacter pylori infection. Dig. Dis. 24, 113-130 (2006).
18. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56, 772-781 (2007). (Pubitemid 46854190)
19. O'Morain C, Broody T, Farley A et al. Efficacy and safety of single triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an International Multicentre Study. Aliment Pharacol Ther. 17, 1-6 (2003).
20. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin and clarithomycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomised, multicenter, North American Trial. Am. J. Gastroenterol. 98, 562-567 (2003).
21. De Boer W. Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection. Eur. J. Gastroenterol. Hepatol. 11(7), 697-700 (1999). (Pubitemid 29349009)
22. De Boer WA. A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule. Expert Opin. Invest. Drugs 10(8), 1559-1566 (2001).
23. De Boer WA, van Etten RJ, Schneeberger PM, Tytgat GN. A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule. Am. J. Gastroenterol. 95(3), 641-645 (2000).
24. De Boer WA, Van Etten RJ, Van De Wouw BA, Schneeberger PM, Van Oijen AH, Jansen JB. Bismuth-based quadruple therapy for Helicobacter pylori - a single triple capsule plus lansoprazole. Aliment. Pharmacol. Ther. 14(1), 85-89 (2000).
25. van Zanten VS, Farley A, Marcon N et al. Bismuth-based triple therapy with bismuth subcitrate, metronidazole and tetracycline in the eradication of Helicobacter pylori: a randomised, placebo controlled, double-blind study. Can. J. Gastroenterol. 14(7), 599-602 (2000). (Pubitemid 30705899)
26. de Boer WA, van Etten RJ, Schneeberger PM, Tytgat GN. A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule. Am. J. Gastroenterol. 95(3), 641-645 (2000).
27. Lahaie R, Farley A, Dallaire C et al. Bismuth-based quadruple therapy with bismuth subcitrate, metronidazole, tetracycline and omeprazole in eradication of Helicobacter pylori. Can. J. Gastroenterol. 15(9), 581-585 (2001). (Pubitemid 33062053)
28. Spenard J, Colin P. Is there a difference in eradication rate of Helicobacter pylori between peptic ulcer patients and non-ulcer dyspepsia patients?: a survey of 1666 patients. Gastroenterology 118(4 Suppl. 2), A502 (2000) (Abstract).
29. Wyeth JW, Pounder RE, Duggan AE et al. The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of Helicobacter pylori. Aliment. Pharmacol. Ther. 10, 623-630 (1996).
30. Coghlin GP, Kupa A, Alp MH. The effect of tripotassium dicitrate bismuthate (De Nol) in the healing of chronic duodenal ulcers. Med. J. Aust. 1, 294-298 (1977). (Pubitemid 8086559)
31. Wilson P, Alp MH. Colloid bismuth subcitrate tablets and placebo in chronic duodenal ulceration. Med. J. Aust. 1, 222-223 (1982).
32. Hamilton I, Worsely BW, O Connor HJ, Axon ATR. Effects of tripotassium dicitrato bismuthate (TDB) tablets or cimetidine in the treatment of duodenal ulcer. Gut 24, 1148-1151 (1983). (Pubitemid 14205817)
33. Hamilton I, O Connor HJ, Wood NC, Bradbury I, Axon ATR. Healing and recurrence of duodenal ulcer after treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine. Gut 27, 106-110 (1986). (Pubitemid 16134485)
34. Martin DF, Hollanders D, May SJ et al. Difference in relapse rate in duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate. Lancet 1(8210), 7-10 (1981). (Pubitemid 11200327)
35. Shreeve DR, Klass HJ, Jones PE. Comparison of cimetidine and tripotassium dicitrato bismuthate in healing and relapse of duodenal ulcers. Digestion 28, 96-101 (1983).
36. Miller JP, Hollanders D, Ravenscroft MM, Tweedle DE, Martin DF. Likelihood of relapse of duodenal ulcer after initial treatment with cimetidine or colloidal bismuth subcitrate. Scand. J. Gastroenterol. 80, 39-42 (1982). (Pubitemid 13175605)
37. Rokkas T, Pursey C, Uzoechina E et al. Non ulcerated dyspepsia and short term De-Nol therapy: a placebo controlled trial with particular reference to the role of Compylobacter pylori. Gut 29, 1386-1391 (1988). (Pubitemid 18250790)
38. Lam SK, Lee NW. Randomised cross over trial of tripotassium dicitrato bismuthate versus high dose cimetidine for duodenal ulcers resistant to standard dose of cimetidine. Gut 25, 703-706 (1984).
39. Locht LJ, Munkoel L, Stoltenberg M et al. Bismuth tracing in organotypic cultures of rat hippocampus. J. Neurosci. Methods 30, 115, 77-83 (2002). (Pubitemid 34202280)
40. Wieriks J, Hespe W, Jairly KD, Koekkoek PH, Lavy U. Pharmacological properties of colloidal bismuth subcitrate (CBS,De-NOL®. Scand. J. Gastroenterol. 17(Suppl. 80), 11-16 (1982).
41. Wagstaff A, Benfield P, Monk J et al. Colloid bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in peptic ulcer disease. Drugs 36, 132-157 (1988). (Pubitemid 18215466)
42. Lee SP. A potential mechanism of action of colloidal bismuth subcitrate: diffusion barrier to hydrochloric acid. Scand. J. Gastroenterol. 17, 17-21 (1982).
43. Coghlan J, Hutchinson L, Gilligan D et al. Dosage of colloidal bismuth subcitrate in duodenal ulcer healing and clearance of Helicobacter pylori. Aliment. Pharmacol. Ther. 4, 49-54 (1990). (Pubitemid 20232690)
44. Lambert JR, Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 11(Suppl. 1), 27-33 (1997). (Pubitemid 127733103)
45. Edwards DI. Nitromidazole drugs-action and resistance mechanism. J. Antimicrob. Chemotherapy 31, 9-20 (1993).
46. Svensson M, Nilsson LE, Strom M, Nilsson M, Sorberg M. Pharmacodynamic effects of nitroimidazole alone and in combination with clarithromycin on Helicobacter pylori. Antimicrob. Agents Chemother. 46, 2244-2248 (2002). (Pubitemid 34665923)
47. Odenholt I, Walder M, Wullt M. Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against C. diff. Chemotherapy 53, 267-274 (2007).
48. O'Connor HJ. The role of Helicobacter pylori in peptic ulcer disease. Scand. J. Gastroenterol. 29(Suppl. 201), 11-15 (1994).
49. O'Connor HJ, Kanduru C, Bhutta A, Meehan JM, Feeley KM. Effects of Helicobacter pylori eradication on peptic ulcer healing. Postgrad. Med. J. 71, 90-93 (1995).
50. O'Connor HJ. Eradication of Helicobacter pylori: therapies and clinical implications, Postgrad. Med. J. 68, 549-557 (1992).
51. Spenard J, Aumais C, Massicotte J, Tremblay C, Lefebvre M. Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline. J. Clin. Pharmacol. 44, 640-645 (2004). (Pubitemid 38668027)
52. Treiber G, Walker S, Klotz U. Omeprazole induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate. Clin. Pharmacol. Ther. 55, 486-491 (1994). (Pubitemid 24192234)
53. De Francesco V, Margiotto M, Zullo A et al. Primary Clarithromycin resistance in Italy assessed on H pylori DNA sequences by Taq Man real time polymerase chain reaction. Aliment. Pharmacol. Ther. 23, 429-435 (2006). (Pubitemid 43382023)
54. Banatvala N, Feldman RA, Abdi Y. High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation to with previous nitromidazole exposure and gastroduodenal disease. Gut 35, 1562-1566 (1994). (Pubitemid 24980359)
55. Goodwin A, Kersulyte D, Sisson G, Veldhuyzen van Zanten SJ, Berg DE, Hoffman PS. Metronidazole resistance in Helicobacter pylori is due to null mutations in a Gene (rdxa) that encodes an oxygen insensitive NADPH nitroreductase. Mol. Microbiol. 28(2), 383-393 (1998). (Pubitemid 28182260)
56. Pilotto A, Franceschi M, Rassu M et al. Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study. Dig. Liver. Dis. 32, 673-675 (2000).
57. Marzio L, Coraggio D, Capodicasa S, Grossi L, Cappello G. Role of the preliminary sucesptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 11, 237-242 (2006). (Pubitemid 44051349)
58. Chey WD, Wong BCY, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology Guideline on the Management of Helicobacter pylori infection. Am. J. Gastrenterol. 102, 1808-1825 (2007).
59. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J. Gastroenterol. Hepatol. 13(1), 1-12 (1998).
60. Saad RJ, Schoenfeld P, Kim HM et al. Levoflaxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a metanalysis. Am. J. Gastroenterol. 101(3), 488-496 (2006). (Pubitemid 46894012)
61. O'Morain C, Montague S. Challenges to therapy in the future. Helicobacter 5(Suppl. 1), S23-S26; discussion S27-S31 (2000).
62. de Boer WA, van Etten RJ, Lai JY, Schneeberger PM, van de Wouw BA, Driessen WM. Effectiveness of quadruple therapy using lansoprozole, instead of omeprazole, in curing Helicobacter pylori infection. Helicobacter 1(3), 145-150 (1996).
63. De Boer W, Driessen W, Jansz A, Tytgat G. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 345(8953), 817-820 (1995).
64. de Boer WA, Driessen WM, Jansz AR, Tytgat GN. Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre study. Eur. J. Gastroenterol. Hepatol. 7(12), 1189-1194 (1995).
65. de Boer WA, van Etten RJ, Schade RW, Ouwehand ME, Schneeberger PM, Tytgat GN. 4 day lansoprozole quadruple therapy: a highly effective cure for Helicobacter pylori infection. Am. J. Gastroenterol. 91(9), 1778-1782 (1996).
66. De Boer WA, Driessen WM, Tytgat GN. Only four days of quadruple therapy can effectively cure Helicobacter pylori infection. Aliment Pharmacol. Ther. 9(6), 633-638 (1995).
67. Hosking SW, Ling TK, Yung MY et al. Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. BMJ 305(6852), 502-504 (1992).
68. Borody TJ, Andrews P, Fracchia G et al. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 37(4), 477-478 (1995).
69. Kung NN, Sung JJ, Yuen NW et al. Anti Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2 day vs 7 day bismuth therapy. Am. J. Gastroenterol. 92(3), 438-441 (1997).
70. Vautier G, Scott BB. A one week quadruple eradication regimen for Helicobacter pylori in routine clinical practice. Alimentar. Pharmacol. Ther. 11(1), 107-108 (1997). (Pubitemid 27067341)
71. van der Hulst RWM, van der Ende A, Homan A, Roorda P, Dankert J, Tytgat GN. Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication. Gut 42(2), 166-169 (1998). (Pubitemid 28212169)
72. Gomollón F, Gimeno L, Valdepérez J, Yus C, Marzo J, Pérez-Caballero MC. Eradication of Helicobacter pylori among patients from a primary care practice. J. Fam. Prac. 43(6), 551-555 (1996).
73. Dore MP. Colloidal bismuth subcitrate-based twice a day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am. J. Gastroenterol. 97, 857-860 (2002).
74. Graham DY, Belson G, Abudayyeh S et al. Twice daily (mid day and evening) quadruple therapy for H. pylori infection in the United States. Dig. Liver Dis. 36, 384-387 (2004). (Pubitemid 41122207)
75. Graham DY, Hoffman J, El-Zimaity HMT, Graham DP, Osata M. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprozole) for treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 11(5), 935-938 (1997).
76. Graham DY, Osato MS, Hoffman J et al. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Alimentar. Pharmacol. Ther. 14(16), 745-750 (2000). (Pubitemid 30352741)
77. de Boer WA, van Etten RJ, Schneeberger PM et al. A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule. Am. J. Gastroenterol. 95, 641-645 (2000).
78. Gene E, Calvet X, Azagra R, Gisbert JP. Triple vs quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment. Pharmacol. Ther. 18(5), 543-544 (2003). (Pubitemid 37152295)
79. Huang JQ, Chiba N, Wilkinson JM, Hunt RH. Attempt by meta-analysis to define the optimal treatment regimen for eradicating Helicobacter pylori (H. pylori) infection. Can. J. Gastroenterol. 11(Suppl. A), 44A (2001).
80. Huang JQ, Hunt RH. Review: eradication of Helicobacter pylori. Problems and recommendations. J. Gastroenterol. Hepatol. 12(8), 590-598 (1997).
81. Ford AC, Malfertheiner P, Giquere M et al. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J. Gastroenterol. 14(48), 7361-7370 (2008).
82. Delves HT. Biomedical applications of ICP-MS. Chem. Br. 24, 1009-1012 (1988).
83. Morrow AW. Request for reports: adverse reactions with bismuth subgallate. Med. J. Aust. 60, 912 (1973).
84. Lagier G. Bismuth encephalopathies outside France (Article in French). Therapie 35, 315-317 (1980). (Pubitemid 10015516)
85. Burns R, Thomas D, Barron V et al. Reversible encephalopathy possibly associated with bismuth subgallate ingestion. BMJ 1, 220-223 (1974).
86. Silkkerveer A, de Wolf FA. Pharmacokinetics and toxicity of bismuth compounds. Med. Toxicol. Adverse Drug Exp. 4(5), 303-323 (1989).
87. Summers WK. Bismuth toxicity masquerading as Alzheimers dementia. J. Alzheimers Dis. 1, 57-59 (1998).
88. Taylor EG, Klenerman P. Acute renal failure after colloidal bismuth subcitrate overdose. Lancet (335), 670-1667 (1990). (Pubitemid 20092704)
89. Phillips RH, Whitehead MW, Doig LA et al. Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe? Helicobacter 6(2), 151-156 (2001).
90. Ford CA, Malfertheiner P, Giquere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systemic review and meta-analysis. World J. Gastroenterol. 14(48), 7361-7370 (2008).